Jing Lin, Diana C. Sahakian, Sonia M. F. de Morais, Jinghai J. Xu, Robert J. Polzer and Steven M. Winter Pages 1125 - 1154 ( 30 )
Major reasons preventing many early candidates reaching market are the inappropriate ADME (absorption, distribution, metabolism and excretion) properties and drug-induced toxicity. From a commercial perspective, it is desirable that poorly behaved compounds are removed early in the discovery phase rather than during the more costly drug development phases. As a consequence, over the past decade, ADME and toxicity (ADMET) screening studies have been incorporated earlier in the drug discovery phase. The intent of this review is to introduce the desirable attributes of a new chemical entity (NCE) to the medicinal chemist from an ADMET perspective. Fundamental concepts, key tools, reagents and experimental approaches used by the drug metabolism scientist to aid a modern project team in predicting human pharmacokinetics and assessing the “drug-like” molecule are discussed.
Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development,Groton Laboratories, Groton, CT 06340, USA